<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bupivacaine and epinephrine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bupivacaine and epinephrine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Bupivacaine and epinephrine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11242" href="/d/html/11242.html" rel="external">see "Bupivacaine and epinephrine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="129654" href="/d/html/129654.html" rel="external">see "Bupivacaine and epinephrine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708635"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Obstetrical anesthesia:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">There have been reports of cardiac arrest with difficult resuscitation or death during use of bupivacaine for epidural anesthesia in obstetrical patients. In most cases, this has followed use of the 0.75% (7.5 mg/mL) concentration. Resuscitation has been difficult or impossible despite apparently adequate preparation and appropriate management. Cardiac arrest has occurred after convulsions resulting from systemic toxicity, presumably following unintentional intravascular injection. The 0.75% (7.5 mg/mL) concentration of bupivacaine is not recommended for obstetrical anesthesia and should be reserved for surgical procedures where a high degree of muscle relaxation and prolonged effect are necessary.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F142997"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Marcaine/Epinephrine;</li>
<li>Marcaine/Epinephrine PF;</li>
<li>Sensorcaine-MPF/EPINEPHrine;</li>
<li>Sensorcaine/EPINEPHrine</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52911943"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Marcaine;</li>
<li>Marcaine E;</li>
<li>Sensorcaine/Epinephrine PF;</li>
<li>Vivacaine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F143008"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Local Anesthetic</li></ul></div>
<div class="block doa drugH1Div" id="F142999"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">Dose varies with procedure, depth of anesthesia, vascularity of tissues, duration of anesthesia, and condition of patient. Do not use solutions containing preservatives for caudal or epidural block. Doses may be repeated up to once every 3 hours (maximum: 400 mg/day of bupivacaine).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="801aba5e-620a-4c44-9877-43e3a6adc3fb">Caudal and lumbar epidural block test dose</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Caudal and lumbar epidural block test dose (preservative free):</b> 2 to 3 mL of 0.5% (maximum: 15 mg/dose of bupivacaine or 15 mcg/dose of epinephrine)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fcb96dfb-a308-4092-a91a-da19c1d5a3e9">Caudal block</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Caudal block (preservative free):</b> 15 to 30 mL of 0.25% or 0.5% (maximum: 75 mg/dose of 0.25% bupivacaine or 150 mg/dose of 0.5% bupivacaine)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="210ac481-1503-4a08-b0f2-a9d784371f1d">Epidural block</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Epidural block (other than caudal block, preservative free):</b> 10 to 20 mL of 0.25% or 0.5% (maximum: 50 mg/dose of 0.25% bupivacaine or 100 mg/dose of 0.5% bupivacaine). Administer in 3 to 5 mL increments, allowing sufficient time to detect toxic manifestations of inadvertent IV or intrathecal administration.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Surgical procedures requiring a high degree of muscle relaxation and prolonged effects only:</i> 10 to 20 mL of 0.75%; <b>Note:</b> Not to be used in obstetrical cases (maximum: 150 mg/dose of bupivacaine)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="806550a8-bbde-4773-bac6-49d476407ccf">Local anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Local anesthesia:</b> Infiltration: 0.25% infiltrated locally (maximum: 400 mg/day of bupivacaine)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f02645aa-c077-48bc-9473-f2947b0646de">Peripheral nerve block</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral nerve block:</b> 5 mL of 0.25% or 0.5% (maximum: 400 mg/day of bupivacaine)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bd7adfdd-e06f-435c-8948-35bab016dff8">Retrobulbar anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Retrobulbar anesthesia:</b> 2 to 4 mL of 0.75% (maximum: 30 mg/dose of bupivacaine)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d126f94-f16c-49ac-828a-06e7809721e4">Sympathetic nerve block</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sympathetic nerve block:</b> 20 to 50 mL of 0.25% (maximum: 125 mg/dose of bupivacaine)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8cd680ec-385f-4b77-978a-08f68e1c09ef">Dental block</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dental block: </b>1.8 mL (9 mg) of bupivacaine as a 0.5% solution with epinephrine 1:200,000 per injection site. A second dose may be administered if necessary to produce adequate anesthesia after allowing up to 10 minutes for onset. Up to a maximum of 90 mg of bupivacaine per dental appointment. The effective anesthetic dose varies with procedure, intensity of anesthesia needed, duration of anesthesia required, and physical condition of the patient; always use the lowest effective dose along with careful aspiration.</p>
<p style="text-indent:-2em;margin-left:2em;">The following numbers of dental carpules (1.8 mL) provide the indicated amounts of bupivacaine 0.5% and vasoconstrictor (epinephrine 1:200,000). See table.</p>
<table border="1" data-table-id="bupepi" frame="void" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="bottom">
<tr>
<th align="center" valign="middle">
<p style="text-indent:0em;"># of Cartridges</p>
<p style="text-indent:0em;">(1.8 mL)</p></th>
<th align="center" valign="middle">
<p style="text-indent:0em;">Mg Bupivacaine</p>
<p style="text-indent:0em;">(0.5%)</p></th>
<th align="center" valign="middle">
<p style="text-indent:0em;">Mg Vasoconstrictor</p>
<p style="text-indent:0em;">(Epinephrine 1:200,000)</p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">1</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">9</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">0.009</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">2</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">18</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">0.018</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">3</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">27</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">0.027</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">4</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">36</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">0.036</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">5</p></td>
<td align="center">
<p style="text-indent:0em;">45</p></td>
<td align="center">
<p style="text-indent:0em;">0.045</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">6</p></td>
<td align="center">
<p style="text-indent:0em;">54</p></td>
<td align="center">
<p style="text-indent:0em;">0.054</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">7</p></td>
<td align="center">
<p style="text-indent:0em;">63</p></td>
<td align="center">
<p style="text-indent:0em;">0.063</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8</p></td>
<td align="center">
<p style="text-indent:0em;">72</p></td>
<td align="center">
<p style="text-indent:0em;">0.072</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">9</p></td>
<td align="center">
<p style="text-indent:0em;">81</p></td>
<td align="center">
<p style="text-indent:0em;">0.081</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">10</p></td>
<td align="center">
<p style="text-indent:0em;">90</p></td>
<td align="center">
<p style="text-indent:0em;">0.090</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Adult doses of bupivacaine hydrochloride with epinephrine cited from USP Dispensing Information (USP DI), 17th ed, The United States Pharmacopeial Convention, Inc, Rockville, MD, 1997, 134.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990322"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doha drugH1Div" id="F50987661"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling. Risk of toxicity may be increased in patients with moderate to severe impairment; consider a reduced dose and more frequent monitoring.</p></div>
<div class="block doe drugH1Div" id="F143000"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F143003"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="129654" href="/d/html/129654.html" rel="external">see "Bupivacaine and epinephrine: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose varies with procedure, depth of anesthesia, vascularity of tissues, duration of anesthesia, and condition of patient; commercially available epinephrine concentrations may not be appropriate in pediatric patients. Preservative-free formulations are recommended for administration into the CNS space (eg, epidural, caudal, spinal). Consider incremental administration with negative aspiration prior to each injection; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided (Mulroy 2010). Should only be administered under the supervision of a qualified physician experienced in the use of anesthetics. In obese pediatric patients, the preferred weight used for dose calculation is undefined and specific pediatric data are sparse (Lerman 2018; Nafiu 2018); some have suggested the use of lean body mass/weight not ideal body weight (IBW) (Coté 2018). Refer to <b>
                        Bupivacaine</b> monograph for specific bupivacaine with or without epinephrine dosing details.</p></div>
<div class="block dorp drugH1Div" id="F51083966"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51083967"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; use with caution.</p></div>
<div class="block adr drugH1Div" id="F142983"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="block coi drugH1Div" id="F142990"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to bupivacaine, epinephrine, amide-type local anesthetics, or any component of the formulation; obstetrical paracervical block anesthesia; IV regional anesthesia (Bier block).</p></div>
<div class="block war drugH1Div" id="F142980"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: Bupivacaine-containing products have been associated with rare occurrences of arrhythmias, cardiac arrest, and death.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intra-articular infusion-related chondrolysis: Continuous intra-articular infusion of local anesthetics after arthroscopic or other surgical procedures is <b>not</b> an approved use; chondrolysis (primarily shoulder joint) has occurred following infusion, with some requiring arthroplasty or shoulder replacement.</p>
<p style="text-indent:-2em;margin-left:4em;">• Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants &lt;6 months of age are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, lightheadedness, fatigue).</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest, especially when administered near the head or neck.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection or administration near the head or neck.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease (including heart block and hypotension) or compromised blood supply.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acutely ill patients: Use with caution in acutely ill patients; dose reduction may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in debilitated patients; dose reduction may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly; dose reduction may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Not recommended for use in children &lt;12 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Obstetrical anesthesia: <b>[US Boxed Warning]:</b>
<b>The bupivacaine 0.75% (7.5 mg/mL) concentration is not recommended for obstetrical anesthesia</b>. <b>There have been reports of cardiac arrest with difficult resuscitation or death during use of bupivacaine for epidural anesthesia in obstetrical patients. In most cases, this has followed use of the 0.75% (7.5 mg/mL) concentration. Resuscitation has been difficult or impossible despite apparently adequate preparation and appropriate management.  Cardiac arrest has occurred after convulsions resulting from systemic toxicity, presumably following unintentional intravascular injection. The 0.75% (7.5 mg/mL) concentration should be reserved for surgical procedures where a high degree of muscle relaxation and prolonged effect are necessary.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Preservative-containing solutions: Do not use solutions containing preservatives for caudal or epidural block.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium metabisulfite: Some commercially available formulations contain sodium metabisulfite, which may cause allergic-type reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Use the lowest effective dose and fractional (incremental) doses when possible; repeat administration may result in accumulation of bupivacaine and metabolites. Intravascular and intrathecal injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular or intrathecal injection has been avoided.</p>
<p style="text-indent:-2em;margin-left:4em;">• Test dose: A test dose is recommended prior to epidural administration (prior to initial dose) and all reinforcing doses with continuous catheter technique.</p>
<p style="text-indent:-2em;margin-left:4em;">• Trained personnel: Dental practitioners and/or clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.</p></div>
<div class="block foc drugH1Div" id="F142987"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Marcaine/Epinephrine: Bupivacaine hydrochloride 0.5% and epinephrine 1:200,000 (50 mL); Bupivacaine hydrochloride 0.25% and epinephrine 1:200,000 (50 mL) [contains edetate (edta) calcium disodium, methylparaben, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Marcaine/Epinephrine: Bupivacaine hydrochloride 0.5% and epinephrine 1:200,000 (50 mL); Bupivacaine hydrochloride 0.25% and epinephrine 1:200,000 (50 mL) [contains methylparaben, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Marcaine/Epinephrine PF: Bupivacaine hydrochloride 0.5% and epinephrine 1:200,000 (10 mL); Bupivacaine hydrochloride 0.25% and epinephrine 1:200,000 (10 mL, 30 mL) [contains edetate (edta) calcium disodium, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sensorcaine/EPINEPHrine: Bupivacaine hydrochloride 0.5% and epinephrine 1:200,000 (50 mL); Bupivacaine hydrochloride 0.25% and epinephrine 1:200,000 (50 mL) [contains methylparaben, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Bupivacaine hydrochloride 0.25% and epinephrine 1:200,000 (50 mL); Bupivacaine hydrochloride 0.5% and epinephrine 1:200,000 (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Marcaine/Epinephrine PF: Bupivacaine hydrochloride 0.5% and epinephrine 1:200,000 (30 mL) [contains edetate (edta) calcium disodium, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Marcaine/Epinephrine PF: Bupivacaine hydrochloride 0.5% and epinephrine 1:200,000 (10 mL, 30 mL); Bupivacaine hydrochloride 0.25% and epinephrine 1:200,000 (10 mL, 30 mL) [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sensorcaine-MPF/EPINEPHrine: Bupivacaine hydrochloride 0.5% and epinephrine 1:200,000 (10 mL, 30 mL); Bupivacaine hydrochloride 0.25% and epinephrine 1:200,000 (10 mL, 30 mL); Bupivacaine hydrochloride 0.75% and epinephrine 1:200,000 (30 mL) [methylparaben free; contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Bupivacaine hydrochloride 0.25% and epinephrine 1:200,000 (10 mL, 30 mL); Bupivacaine hydrochloride 0.5% and epinephrine 1:200,000 (10 mL, 30 mL)</p></div>
<div class="block geq drugH1Div" id="F142976"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323028"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (BUPivacaine-EPINEPHrine (PF) Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25%-1:200000 (per mL): $0.53 - $0.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5%-1:200000 (per mL): $0.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (BUPivacaine-EPINEPHrine Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25%-1:200000 (per mL): $0.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5%-1:200000 (per mL): $0.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Marcaine/Epinephrine Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25%-1:200000 (per mL): $0.29</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25-1:200000% (per mL): $0.29</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5%-1:200000 (per mL): $0.39</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Marcaine/Epinephrine PF Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25%-1:200000 (per mL): $0.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25-1:200000% (per mL): $0.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5%-1:200000 (per mL): $0.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Sensorcaine-MPF/EPINEPHrine Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25%-1:200000 (per mL): $0.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5%-1:200000 (per mL): $0.33</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.75-1:200000% (per mL): $0.47</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Sensorcaine/EPINEPHrine Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25%-1:200000 (per mL): $0.37</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5%-1:200000 (per mL): $0.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F53475767"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Marcaine: Bupivacaine hydrochloride 0.5% and epinephrine 1:200,000 (1.8 mL) [contains edetate (edta) calcium disodium, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Marcaine E: Bupivacaine hydrochloride 0.5% and epinephrine 1:200,000 (3 mL, 20 mL); Bupivacaine hydrochloride 0.25% and epinephrine 1:200,000 (20 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sensorcaine/Epinephrine PF: Bupivacaine hydrochloride 0.5% and epinephrine 1:200,000 (20 mL); Bupivacaine hydrochloride 0.25% and epinephrine 1:200,000 (20 mL) [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vivacaine: Bupivacaine hydrochloride 0.5% and epinephrine 1:200,000 (1.8 mL) [contains edetate (edta) calcium disodium, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Bupivacaine hydrochloride 0.5% and epinephrine 1:200,000 (1.8 mL)</p></div>
<div class="block adm drugH1Div" id="F27107020"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;">Solutions containing preservatives should not be used for epidural or caudal blocks. The On-Q infusion pump is used to slowly administer local anesthetics (eg, bupivacaine, lidocaine, ropivacaine) to or around surgical wound sites and/or in close proximity to nerves for pre- or postoperative regional anesthesia. When infused directly into the shoulder, destruction of articular cartilage (chondrolysis) has occurred. On-Q® pumps should never be placed directly into any joint (see https://www.ismp.org/Newsletters/acutecare/archives/May09.asp).</p></div>
<div class="block admp drugH1Div" id="F52612329"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Solutions containing preservatives should not be used for epidural or caudal blocks; for epidural infusion, may use undiluted or diluted with preservative-free NS. Consider incremental administration with negative aspiration prior to each injection; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided (Mulroy 2010).</p></div>
<div class="block use drugH1Div" id="F2234382"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Anesthesia/analgesia:</b> Local or regional anesthesia or analgesia for surgery, dental and oral procedures, diagnostic and therapeutic procedures, and obstetrical procedure</p>
<p style="text-indent:-2em;margin-left:4em;">0.25%: Local infiltration, peripheral nerve block, sympathetic block, lumbar epidural, or caudal</p>
<p style="text-indent:-2em;margin-left:4em;">0.5%: Peripheral nerve block, lumbar epidural, caudal, epidural test dose, or dental blocks</p>
<p style="text-indent:-2em;margin-left:4em;">0.75% <b>(not for obstetrical anesthesia)</b>: Retrobulbar block or lumbar epidural; <b>Note:</b> Reserve for surgical procedures where a high degree of muscle relaxation and prolonged effect are necessary.</p></div>
<div class="block mst drugH1Div" id="F5977943"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F143004"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F142984"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azosemide: May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypertensive effect of EPINEPHrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (with Alpha-Blocking Properties): May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bretylium: May enhance the therapeutic effect of Alpha-/Beta-Agonists (Direct-Acting).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Management: Consider alternatives to this combination when possible. If combined, monitor for hypertension and tachycardia, and do not coadminister these agents for more than 10 days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine (Liposomal): BUPivacaine may enhance the adverse/toxic effect of BUPivacaine (Liposomal).  Management: Bupivacaine may be administered immediately before, or administered in the same admixture syringe as liposomal bupivacaine as long as the ratio of the milligram dose of bupivacaine to liposomal bupivacaine does not exceed 1:2.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroprocaine (Systemic): May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: May diminish the therapeutic effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COMT Inhibitors: May increase the serum concentration of COMT Substrates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloPHOSphamide: May enhance the adverse/toxic effect of BUPivacaine. Specifically, the risk of methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): May enhance the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: May diminish the vasoconstricting effect of EPINEPHrine (Systemic). Management: Consider alternatives to this combination and monitor for reduced epinephrine efficacy, and possible paradoxical effects (ie, hypotension), when combined. Use of alternative vasopressor agents (eg, phenylephrine, metaraminol, norepinephrine) is preferred.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Do not use hyaluronidase to enhance the dispersion or absorption of alpha-/beta-agonists. Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydroxyurea: May enhance the adverse/toxic effect of BUPivacaine. Specifically, the risk of methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: May enhance the adverse/toxic effect of BUPivacaine. Specifically, the risk of methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhalational Anesthetics: May enhance the arrhythmogenic effect of EPINEPHrine (Systemic). Management: Administer epinephrine with added caution in patients receiving, or who have recently received, inhalational anesthetics. Use lower than normal doses of epinephrine and monitor for the development of cardiac arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoproterenol: May enhance the therapeutic effect of EPINEPHrine (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: May enhance the adverse/toxic effect of BUPivacaine. Management: Avoid using any additional local anesthetics within 96 hours after insertion of the bupivacaine implant (Xaracoll) or bupivacaine and meloxicam periarticular solution (Zynrelef) or within 168 hours after subacromial infiltration (Posimir brand).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of EPINEPHrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrous Oxide: May enhance the adverse/toxic effect of BUPivacaine. Specifically, the risk of methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pergolide: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promethazine: May diminish the vasoconstricting effect of EPINEPHrine (Systemic). Management: Avoid epinephrine and consider norepinephrine or phenylephrine when treating hypotension due to promethazine overdose. Consider alternative vasocontrictors in patients treated with promethazine. This combination may be indicated in anaphylaxis treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: May increase the serum concentration of BUPivacaine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: If possible, avoid coadministration of direct-acting alpha-/beta-agonists and serotonin/norepinephrine reuptake inhibitors. If coadministered, monitor for increased sympathomimetic effects (eg, increased blood pressure, chest pain, headache).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept.  Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: Avoid, if possible, the use of alpha-/beta-agonists in patients receiving tricyclic antidepressants. If combined, monitor for evidence of increased pressor effects and consider reductions in initial dosages of the alpha-/beta-agonist.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May enhance the adverse/toxic effect of BUPivacaine. Specifically, the risk of methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasopressin: Alpha-/Beta-Agonists (Direct-Acting) may enhance the hypertensive effect of Vasopressin. The effect of other hemodynamic parameters may also be enhanced. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F2234383"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">
<b>[US Boxed Warning]: </b>
<b>The bupivacaine 0.75% (7.5 mg/mL) concentration is not recommended for obstetrical anesthesia.</b>
<b>There have been reports of cardiac arrest with difficult resuscitation or death during use of bupivacaine for epidural anesthesia in obstetrical patients. In most cases, this has followed use of the 0.75% (7.5 mg/mL) concentration. Resuscitation has been difficult or impossible despite apparently adequate preparation and appropriate management. </b>
<b></b>
<b>Cardiac arrest has occurred after convulsions resulting from systemic toxicity, presumably following unintentional intravascular injection. The 0.75% (7.5 mg/mL) concentration should be reserved for surgical procedures where a high degree of muscle relaxation and prolonged effect are necessary.</b></p>
<p style="text-indent:0em;margin-top:2em;">Use in obstetrical paracervical block anesthesia is contraindicated (may cause fetal bradycardia and death).</p>
<p style="text-indent:0em;margin-top:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block brc drugH1Div" id="F54950917"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Bupivacaine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block mop drugH1Div" id="F2234496"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Vital signs, state of consciousness; signs of CNS toxicity</p></div>
<div class="block pha drugH1Div" id="F142979"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Local anesthetics bind selectively to the intracellular surface of sodium channels to block influx of sodium into the axon. As a result, depolarization necessary for action potential propagation and subsequent nerve function is prevented. The block at the sodium channel is reversible. When drug diffuses away from the axon, sodium channel function is restored and nerve propagation returns. </p>
<p style="text-indent:0em;margin-top:2em;text-align:justify;">Epinephrine prolongs the duration of the anesthetic actions of bupivacaine by causing vasoconstriction (alpha-adrenergic receptor agonist) of the vasculature surrounding the nerve axons. This prevents the diffusion of bupivacaine away from the nerves resulting in a longer retention in the axon</p></div>
<div class="block phk drugH1Div" id="F142989"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Refer to Bupivacaine; epinephrine reduces the rate of absorption and peak plasma concentration of bupivacaine</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-1397990">
<a name="1397990"></a>Ayoub ST and Coleman AE, “A Review of Local Anesthetics,” <i>Gen Dent</i>, 1992, 40(4):285-7, 289-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-and-epinephrine-drug-information/abstract-text/1397990/pubmed" id="1397990" target="_blank">1397990</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Coté CJ, ed. <i>A Practice of Anesthesia for Infants and Children</i>. 6th ed. Elsevier Inc; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21263316">
<a name="21263316"></a>Dix SK, Rosner GF, Nayar M, et al, “Intractable Cardiac Arrest Due to Lidocaine Toxicity Successfully Resuscitated With Lipid Emulsion,” <i>Crit Care Med</i>, 2011, 39(4):872-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-and-epinephrine-drug-information/abstract-text/21263316/pubmed" id="21263316" target="_blank">21263316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12436829">
<a name="12436829"></a>Finder RL and Moore PA, “Adverse Drug Reactions to Local Anesthesia,” <i>Dent Clin North Am</i>, 2002, 46(4):747-57, x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-and-epinephrine-drug-information/abstract-text/12436829/pubmed" id="12436829" target="_blank">12436829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20592403">
<a name="20592403"></a>Garisto GA, Gaffen AS, Lawrence HP, et al, "Occurrence of Paresthesia After Dental Local Anesthetic Administration in the United States," <i>J Am Dent Assoc</i>, 2010, 141(7):836-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-and-epinephrine-drug-information/abstract-text/20592403/pubmed" id="20592403" target="_blank">20592403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6355236">
<a name="6355236"></a>Jastak JT and Yagiela JA, “Vasoconstrictors and Local Anesthesia: A Review and Rationale for Use,” <i>J Am Dent Assoc</i>, 1983, 107(4):623-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-and-epinephrine-drug-information/abstract-text/6355236/pubmed" id="6355236" target="_blank">6355236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29697466">
<a name="29697466"></a>Lerman J, Becke K. Perioperative considerations for airway management and drug dosing in obese children. <i>Curr Opin Anaesthesiol</i>. 2018;31(3):320-326.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-and-epinephrine-drug-information/abstract-text/29697466/pubmed" id="29697466" target="_blank">29697466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8185087">
<a name="8185087"></a>MacKenzie TA and Young ER, “Local Anesthetic Update,” <i>Anesth Prog</i>, 1993, 40(2):29-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-and-epinephrine-drug-information/abstract-text/8185087/pubmed" id="8185087" target="_blank">8185087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12733413">
<a name="12733413"></a>Malamed SF, “Allergy and Toxic Reactions to Local Anesthetics,” <i>Dent Today</i>, 2003, 22(4):114-6, 118-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-and-epinephrine-drug-information/abstract-text/12733413/pubmed" id="12733413" target="_blank">12733413</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Marcaine (bupivacaine/epinephrine) [prescribing information]. Lake Forest, IL: Hospira Inc; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20216035">
<a name="20216035"></a>Mulroy MF, Hejtmanek MR. Prevention of local anesthetic systemic toxicity. <i>Reg Anesth Pain Med</i>. 2010;35(2):177-180.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-and-epinephrine-drug-information/abstract-text/20216035/pubmed" id="20216035" target="_blank">20216035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29200076">
<a name="29200076"></a>Nafiu OO, Mills K, Tremper KK. Some cautionary tales about ideal body weight dosing of anesthetic medications: it is not all that ideal!. <i>Anesth Analg</i>. 2018;127(2):586-588.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-and-epinephrine-drug-information/abstract-text/29200076/pubmed" id="29200076" target="_blank">29200076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22189574">
<a name="22189574"></a>Neal JM, Mulroy MF, and Weinberg GL, “American Society of Regional Anesthesia and Pain Medicine Checklist for Managing Local Anesthetic Systemic Toxicity: 2012 Version,” <i>Reg Anesth Pain Med</i>, 2012, 37(1):16-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-and-epinephrine-drug-information/abstract-text/22189574/pubmed" id="22189574" target="_blank">22189574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sensorcaine.1">
<a name="Sensorcaine.1"></a>Sensorcaine (bupivacaine and epinephrine) [prescribing information]. Lake Zurich, IL: Fresenius Kabi; November 2022.</div>
</li>
<li>
<div class="reference">
                  Sensorcaine with Epinephrine (bupivacaine and epinephrine) [product monograph]. Oakville, Ontario, Canada: Aspen Pharmacare Canada Inc; November 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sensorcaine.3">
<a name="Sensorcaine.3"></a>Sensorcaine with Epinephrine and Sensorcaine-MPF with Epinephrine (bupivacaine and epinephrine) [prescribing information]. Lake Zurich, IL: Fresenius Kabi; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7911769">
<a name="7911769"></a>Wynn RL, “Epinephrine Interactions With Beta-Blockers,” <i>Gen Dent</i>, 1994, 42(1):16, 18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-and-epinephrine-drug-information/abstract-text/7911769/pubmed" id="7911769" target="_blank">7911769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1819966">
<a name="1819966"></a>Yagiela JA, “Local Anesthetics,” <i>Anesth Prog</i>, 1991, 38(4-5):128-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-and-epinephrine-drug-information/abstract-text/1819966/pubmed" id="1819966" target="_blank">1819966</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8821 Version 301.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
